Literature DB >> 23649999

Reoperations of patients with low-grade gliomas in eloquent or near eloquent brain areas.

Wojciech Kaspera1, Krzysztof Majchrzak, Barbara Bobek-Billewicz, Anna Hebda, Gabriela Stasik-Pres, Henryk Majchrzak, Piotr Ladziński, Agnieszka Machowska-Majchrzak.   

Abstract

BACKGROUND AND
PURPOSE: Reoperations of patients with recurrent low-grade gliomas (LGG) are not always recommended due to a higher risk of neurological deficits when compared to initial surgery. The purpose of the present study was to evaluate surgical outcomes of patients operated on for recurrent LGG.
MATERIAL AND METHODS: Sixteen patients who had surgery for recurrent LGG out of 68 LGG patients who underwent surgery at the Department of Neurosurgery in Sosnowiec, Poland between 2005 and 2011 were enrolled in the study.
RESULTS: A large tumour volume prior to the initial surgery was the most significant parameter influencing LGG progression (96.6 cm³ vs. 47.9 cm3, p = 0.01). Increased incidence of epileptic seizures and decreased mental ability according to Karnofsky score were the most common symptoms associated with tumour recurrence. In the group of patients with malignant transformation, the relative cerebral blood volume (rCBV) was considerably increased (1.21 vs. 2.41, p < 0.01). No statistically significant difference was found in terms of the extent of resection between initial surgery and reoperation. Similarly, no significant difference was found in the number of patients with a permanent neurological deficit after initial surgery and reoperation.
CONCLUSIONS: Reoperations of the patients with recurrent LGG are not burdened with a higher risk of neurological sequelae when compared to initial surgery. The extent of resection during the surgery for LGG recurrence is comparable to initial surgery. The increase of rCBV seems to be a significant biomarker that indicates malignant transformation.

Entities:  

Mesh:

Year:  2013        PMID: 23649999     DOI: 10.5114/ninp.2013.34399

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  4 in total

1.  Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma.

Authors:  Chaeyeong Kim; Gyeyeong Kong; Hyunji Lee; Quangdon Tran; Thuy-Trang T Vo; So Hee Kwon; Jisoo Park; Seon-Hwan Kim; Jongsun Park
Journal:  Toxicol Res       Date:  2022-02-25

Review 2.  Repeated Awake Surgical Resection(s) for Recurrent Diffuse Low-Grade Gliomas: Why, When, and How to Reoperate?

Authors:  Hugues Duffau
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

3.  Using cortical function mapping by awake craniotomy dealing with the patient with recurrent glioma in the eloquent cortex.

Authors:  Ying-Ching Li; Hsiao-Yean Chiu; Kuo-Chen Wei; Ya-Jui Lin; Ko-Ting Chen; Peng-Wei Hsu; Yin-Cheng Huang; Pin-Yuan Chen
Journal:  Biomed J       Date:  2020-06-12       Impact factor: 7.892

Review 4.  Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.

Authors:  Wojciech Szopa; Thomas A Burley; Gabriela Kramer-Marek; Wojciech Kaspera
Journal:  Biomed Res Int       Date:  2017-02-20       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.